Yi Jer Tan1, Yeuan Ting Lee1, Keng Yoon Yeong1,2, Sven H Petersen3, Koji Kono3,4,5, Soo Choon Tan1, Chern Ein Oon1. 1. Institute for Research in Molecular Medicine (INFORMM), Universiti Sains Malaysia, Penang, 11800, Malaysia. 2. School of Science, Monash University Malaysia Campus, Jalan Lagoon Selatan, Bandar Sunway, 47500, Selangor, Malaysia. 3. Cancer Science Institute of Singapore, National University of Singapore, Singapore, Singapore. 4. Department of Surgery, National University of Singapore, Singapore, Singapore. 5. School of Medicine, Fukushima Medical University, Fukushima, Japan.
Abstract
AIM: This study aims to investigate the mode of action of a novel sirtuin inhibitor (BZD9L1) and its associated molecular pathways in colorectal cancer (CRC) cells. MATERIALS & METHODS: BZD9L1 was tested against metastatic CRC cell lines to evaluate cytotoxicity, cell cycle and apoptosis, senescence, apoptosis related genes and protein expressions, as well as effect against major cancer signaling pathways. RESULTS & CONCLUSION: BZD9L1 reduced the viability, cell migration and colony forming ability of both HCT 116 and HT-29 metastatic CRC cell lines through apoptosis. BZD9L1 regulated major cancer pathways differently in CRC with different mutation profiles. BZD9L1 exhibited anticancer activities as a cytotoxic drug in CRC and as a promising therapeutic strategy in CRC treatment.
AIM: This study aims to investigate the mode of action of a novel sirtuin inhibitor (BZD9L1) and its associated molecular pathways in colorectal cancer (CRC) cells. MATERIALS & METHODS: BZD9L1 was tested against metastatic CRC cell lines to evaluate cytotoxicity, cell cycle and apoptosis, senescence, apoptosis related genes and protein expressions, as well as effect against major cancer signaling pathways. RESULTS & CONCLUSION: BZD9L1 reduced the viability, cell migration and colony forming ability of both HCT 116 and HT-29 metastatic CRC cell lines through apoptosis. BZD9L1 regulated major cancer pathways differently in CRC with different mutation profiles. BZD9L1 exhibited anticancer activities as a cytotoxic drug in CRC and as a promising therapeutic strategy in CRC treatment.
Authors: Ming Hung Lin; Atikul Islam; Yen-Hui Liu; Chia-Wei Weng; Jun-Han Zhan; Ru-Hao Liang; Alexander S Tikhomirov; Andrey E Shchekotikhin; Pin Ju Chueh Journal: Am J Cancer Res Date: 2022-03-15 Impact factor: 6.166
Authors: Yi Jer Tan; Yeuan Ting Lee; Sven H Petersen; Gurjeet Kaur; Koji Kono; Soo Choon Tan; Amin M S Abdul Majid; Chern Ein Oon Journal: Ther Adv Med Oncol Date: 2019-09-27 Impact factor: 8.168